Gsk Share Discussion Threads

[geckotheglorious] 13/5/2021 12:23

CureVac (CVAC) shares rise 5% on encouraging CV2CoV data against COVID-19 variants

CureVac (NASDAQ:CVAC) and collaboration partner GlaxoSmithKline (NYSE:GSK) announce the first preclinical data from second-generation COVID-19 vaccine candidate, CV2CoV in a rat model.

CV2CoV is based on a new mRNA backbone, which differs from CureVac's first-generation vaccine candidate, CVnCoV, currently in late-stage clinical testing.

Preclinical data demonstrated CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.

In addition, the serum of vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the U.K. (B.1.1.7) and South Africa (B.1.351).

First clinical trials for CV2CoV are expected to start in Q3 2021.

[geckotheglorious] 13/5/2021 10:18

That is my suspicion Spud.

[spud] 13/5/2021 10:00

Recovery implies good news. The media doesn't deal in good news as there's less money to be had. spud

[geckotheglorious] 13/5/2021 09:57

True but it is still nice to know them - John Hopkins site has hidden recovery numbers, they used to be easily accessible, and seemingly replaced them with Vaccine numbers.

I don't care what the vaccine numbers are - recovery numbers are far more important in my view.

[thamestrader] 13/5/2021 08:29

The recovery numbers for UK were never real anyway. Certainly not comparable to other countries, as we measure them very differently.

[geckotheglorious] 13/5/2021 08:22

So, where have the "hidden" the Recovery numbers this time????



Before you had a tab on the deaths section that would also take you to Recoveries.
I can't see that...

Anyone else??

[ianood] 12/5/2021 16:33

You could say that others are a tad more obtuse:)

[spud] 12/5/2021 16:10

Monty is a contrary indicator.

spud

[abdullla] 12/5/2021 15:13

Yes good timing clever as a Fox .

[eurofox] 12/5/2021 14:28

so much for Monty extolling the marvels of waiting for 1250p as a re-entry point - I did my topping up at 1320p

[alex1621] 12/5/2021 14:02

They are all at the Elliot meeting.

[abdullla] 12/5/2021 13:55

Whats up Doc ?where is everyone?

[rikky72] 11/5/2021 23:32

Think it's worth mentioning that this activist investor, who has attracted much chatter and column inches, can't necessarily do anything magical to turn this Pollock into a Da Vinci. It would take a lot of investment, smart risk taking, and, yes, some measure of luck to turn this into what we all hope it would or could be. But streamlining operations and cutting costs are simpler where business models are more straightforward. The split still confuses the hell out of me. I have no idea if the two separate entities will be worth £10or £20 of the equivalent GSK today. If this ever got near £17 before the split though I would sell my entire holding that I've held for almost 20 years, no question.

[geckotheglorious] 11/5/2021 21:14

Following up on "Ivermectin angle" in case anyone interested.

"Ivermectin prophylactic study from India - Dr John Campbell"
Ivermectin in India, Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers


​


Background
Healthcare workers (HCWs) are vulnerable to getting infected withSARS-CoV-2
Preventing HCWs from getting infected is a priority to maintain healthcare services

The therapeutic and preventive role of ivermectin in COVID-19 is being investigated
Based on promising results of in vitro studies of oral ivermectin,
this study to look at prophylactic role of oral ivermectin

Methods
Prospective cohort study was conducted at AIIMS Bhubaneswar
Two-doses of oral ivermectin, 300 μg/kg at a gap of 72 hours


Primary outcome, COVID-19 infection in the month following
Of 3892 employees, 3532 (90.8%) participated in the study

Ivermectin uptake n = 2, 384 (67.5%)
Non uptake, n = 1147 (32.5%)

Results
Development of symptomatic infection
331 participants, developed symptoms
131 in takers
200 from non takers

Ivermectin takers, 6%
Non takers, 15%

Testing positive, 201
Ivermectin takers, 2%
Non takers, 11.7%

Implications for transmission

HCWs who had taken two-doses
(Single dose did not reach significance)

Significantly lower risk of contracting COVID-19 disease during the following month was 0.18

Adjusted Relative Risk 0.17

1.8% reported adverse events, mild and self-limiting

Conclusion and relevance
Two-doses of oral ivermectin (300 μg/kg given 72 hours apart) as chemoprophylaxis among HCWs
reduces the risk of COVID-19 infection by 83% in the following month.

Safe, effective, and low-cost chemoprophylaxis have relevance in the containment of pandemic
alongside vaccine.


​

AIIMS Director, Gitanjali Batmanabane

Earlier, at least 20 to 25 HCWs were getting infected with the virus daily.
After the workers started taking ivermectin, the number of infection has come down to one or two per day

Critique

The safety of the drug has been established by its large-scale use in the last four decades for
various indications such as onchocerciasis, scabies, head lice, and other parasitic infestations

[alex1621] 11/5/2021 16:50

It's called The Caesars Palace Coup. And the authors are Max Frumes and Sunjeet Indap. It's a complex story involving an assortment of Wall St participants ... private equity, hedge funds, white shoe law firms.

[williamcooper104] 11/5/2021 16:08

What's the book called Elliot and Apollo got into an epic fight on that one - Apollo's behaviour was at best borderline legal

[williamcooper104] 11/5/2021 16:06

Activists usually go in first with the board - they only go public if the board doesn't do what they want

[alex1621] 11/5/2021 16:06

I'm reading a book at the moment called the Caesars Palace Coup about a complicated legal fight between the private equity owners of Caesars Entertainment (casino) and its bond holders. Elliot Management were senior bond holders, and according to the book they do extensive research before spending a cent, and are ruthless sharks. Haven't finished it yet but half way through and I'm beginning to see their reputation is well deserved.

[abdullla] 11/5/2021 16:02

Losing a few quid on CFDs is peanuts for someone who deals in Billions.

[alex1621] 11/5/2021 15:43

Monty, get on that phone to New York, as he clearly has no idea what he's doing, poor chap.

[montyhedge] 11/5/2021 14:55

If he has got cfds in GSK it's costing him money to keep it running each day, can't make out why Elliott have not said anything all through hearsay with financial journalist's.

[eurofox] 11/5/2021 13:24

I don't care what you think i should do Monty - I have a mind and valuation of my own

[abdullla] 11/5/2021 13:23

At this low price it gives Elliots an opportunity to buy big and go for the kill.

[montyhedge] 11/5/2021 13:06

This dog shareprice below what it was 25 years ago. Not only a dog but a dog with fleas.Elliott can't do anything.